Neuromodulators: acetylcholine, norepinephrine, epinephrine, vasopressin, histamine, arginine, serotonin, dopamine, autocrine agents, and $\beta$-endorphin.
I am aware that agonists of the $\alpha_7 $ nAChRs improve cognition in Schizophrenia, presumably by catalysing the release of histamine, norepinephrine and/or acetylcholine.1,2 I also know that $\alpha_7 $ nAChRs antagonists reduce $\Delta^9$-tetrahydrocannabinol (THC) self-administration in mice presumably by suppressing dopaminergic activity in the nucleus accumbens or by inhibiting the activity of the CB1 receptor.3 Selective CB1 antagonists also manage to reduce nicotine dependence.4 Also I know that the activation of the $ \alpha_3 \beta_4 $ nAChRs in the adrenal medulla catalyses an epinephrine and norepinephrine release.
Reference List (Oxford Style)
- M Hajós, BN Rogers, 'Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia.', Current Pharmaceutical Design, 16/5 (2010), 538-554.
- LF Martin, WR Kem, R Freedman, 'Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia', Psychopharmacology, 174/1 (2004), 54-64.
- M Solinas, M Scherma, L Fattore, J Stroik, C Wertheim, G Tanda, W Fratta, SR Goldberg, 'Nicotinic α7 Receptors as a New Target for Treatment of Cannabis Abuse', The Journal of Neuroscience, 27/21 (2007), 5615-5620.
- C Cohen, E Kodas, G Griebel, 'CB1 receptor antagonists for the treatment of nicotine addiction.', Pharmacology, Biochemistry and Behavior, 81/2 (2005), 387-395.